Mechanism of Action
KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 ...
KBP-5074 Achieves 10.1 mmHg reduction in systolic blood pressure (SBP) at 0.5mg dose compared to pla...
Dec 07, 2020
KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074
KBP-5074 Being Evaluated for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney D...
Aug 11, 2020
KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript f...
KBP-5074 is a highly-selective non-steroidal mineralocorticoid receptor antagonist with potentially ...
Jun 30, 2020
KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in se...
Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or.....
May 21, 2020
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074
KBP-5074, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Under Evaluation for the Treatmen.....
May 20, 2020
KBP BIOSCIENCES SIGNS MEMORANDUM OF UNDERSTANDING WITH BULLFROG AI
PRINCETON, N.J., January 8, 2020 — KBP BioSciences, a clinical stage biotechnology company dedicated
Aug 08, 2019